What is Kodiak Sciences?
Headquartered in Palo Alto, California, Kodiak Sciences is dedicated to the research, development, and commercialization of novel therapeutics targeting retinal diseases. The company's core value proposition centers on its Antibody Biopolymer Conjugate (ABC) platform, which aims to improve the durability and efficacy of treatments for conditions such as wet age-related macular degeneration (AMD) and diabetic macular edema. By leveraging advanced protein engineering, the firm seeks to address the limitations of current anti-VEGF therapies, which often require frequent intravitreal injections. The company's lead candidate, tarcocimab tedromer, represents a significant milestone in its clinical development roadmap, currently undergoing rigorous Phase IIb/III testing to validate its therapeutic profile. As a specialized biopharma entity, Kodiak Sciences operates at the intersection of molecular biology and clinical medicine, focusing on high-unmet-need markets where long-acting, potent therapeutics can command substantial market share.
How much funding has Kodiak Sciences raised?
Kodiak Sciences has raised a total of $476.4M across 6 funding rounds:
Other Financing Round
$1.8M
Series B
$34M
Debt
$33M
Stock Offering
$90M
Stock Offering
$317.4M
Debt
$150K
Other Financing Round (2009): $1.8M with participation from Undisclosed
Series B (2016): $34M led by Undisclosed
Debt (2018): $33M supported by ArrowMark Partners and Perceptive Advisors
Stock Issuance/Offering (2018): $90M featuring Undisclosed
Stock Issuance/Offering (2019): $317.4M backed by Undisclosed
Debt (2020): $150K with participation from PPP
Key Investors in Kodiak Sciences
Perceptive Advisors
Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment firm managing around $7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
ArrowMark Partners
An investment management firm that provides capital solutions to growth-oriented companies, often focusing on specialized sectors including healthcare and technology.
Undisclosed Investors
What's next for Kodiak Sciences?
Looking ahead, the strategic focus for Kodiak Sciences remains the successful completion of its ongoing clinical trials and the subsequent regulatory submission process for its lead assets. The capital secured through recent financing rounds provides the necessary runway to support these intensive Phase III studies and prepare for potential commercialization. Investors are closely monitoring the data readouts for tarcocimab tedromer, as positive results would serve as a critical catalyst for the company's valuation and long-term growth trajectory. Furthermore, the firm is expected to continue exploring the versatility of its bispecific protein platform, potentially expanding its pipeline into other inflammatory retinal conditions. As the company transitions from a research-heavy entity to a potential commercial-stage organization, maintaining operational efficiency and clinical excellence will be paramount to sustaining its competitive advantage in the global biopharmaceutical market.
See full Kodiak Sciences company page
